Table 6.
Payments from the top 10 companies with general payments to practicing radiation oncologists, 2014–2018
| Company Name | Number of Payments, all years | Total Value of General Payments, USD | Top Product(s) | |||||
|---|---|---|---|---|---|---|---|---|
| 2014 | 2015 | 2016 | 2017 | 2018 | all years | |||
| Boston Scientific Corporation | 181 | $1,075 | $1,553 | $21,530 | $6,827 | $17,672,413 | $17,703,399 | includes Augmenix purchase and ownership interest payment for hydrogel spacer |
| Bayer HealthCare Pharmaceuticals Inc. | 9,988 | $694,735 | $573,046 | $766,780 | $419,337 | $322,446 | $2,776,344 | radium Ra 223 dicholoride, regorafenib, sorafenib |
| Varian Medical Systems, Inc. | 8,547 | $287,845 | $445,503 | $948,593 | $548,928 | $461,806 | $2,692,675 | linear accelerator, proton cyclotron |
| AstraZeneca Pharmaceuticals LP | 3,988 | $61,065 | $235,195 | $1,244,666 | $469,598 | $389,660 | $2,400,184 | durvalumab, osimertinib, fulvestrant |
| INSYS Therapeutics, Inc. | 9,051 | $134,586 | $500,339 | $880,503 | $411,983 | $109,657 | $2,037,069 | fentanyl (sublingual), dronabinol |
| iCAD, Inc. | 568 | $71,578 | $215,003 | $580,642 | $255,366 | $107,286 | $1,229,874 | electronic brachytherapy controller |
| Novocure, Inc. | 4,901 | $57,124 | $126,083 | $505,525 | $217,448 | $317,893 | $1,224,074 | alternating electric field therapy |
| Amendia, Inc. | 2 | $0 | $0 | $1,066,668 | $0 | $0 | $1,066,668 | not identified (ownership interest) |
| Augmenix, Inc. | 2,224 | $0 | $22,314 | $271,603 | $330,682 | $429,424 | $1,054,023 | hydrogel spacer |
| E.R. Squibb & Sons, L.L.C. | 10,351 | $229,643 | $151,070 | $254,134 | $233,889 | $120,042 | $988,778 | nivolumab, cetuximab, elotuzumab |
Abbreviations: USD, 2014 United States dollars. Generic or generalized terms are used for product names.